Introduction
============

Frontotemporal lobar degeneration (FTLD) is a term covering a heterogeneous group of neurodegenerative disorders with predominant atrophy of the frontal and/or the temporal lobes of the brain. It is the third most common form of dementia after Alzheimer's disease and vascular dementia, and accounts for 5--10% of all dementia patients ([@awv358-B32]). In individuals younger than 65 years, it is the second most common cause of dementia after Alzheimer's disease.

FTLD is remarkably heterogeneous in clinical presentation, neuropathological characteristics and underlying genetic causes. Clinically, frontotemporal dementia (FTD) is characterized by a progressive deterioration in behaviour, personality and/or language with relative preservation of memory function. It can be divided in two clinical subtypes: a behavioural variant, and a language variant or primary progressive aphasia (PPA). PPA can be further subdivided into progressive non-fluent aphasia, semantic dementia and logopenic progressive aphasia, although the latter is frequently associated with underlying atypical Alzheimer's disease pathology ([@awv358-B21]). Pathologically, FTLD is divided in different subclasses according to the major inclusion protein that is found in protein depositions in degenerating neurons: TAR DNA binding protein 43 (TDP-43, encoded by *TARDBP*; FTLD-TDP), microtubule associated protein tau (MAPT, FTLD-tau), FUS RNA binding protein (FUS, FTLD-FUS) or no inclusions (FTLD-ni) ([@awv358-B24])*.* Clinical and population-based studies showed that FTD is familial in 30--50% of patients, with an autosomal dominant inheritance in up to 40% ([@awv358-B20]). About 17--40% of Mendelian inherited forms of FTD are explained by a mutation in *GRN*, *MAPT* or *C9orf72* and more rarely by a mutation in *VCP* or *CHMP2B* ([@awv358-B36])*.*

About 15% of patients with FTD also develop amyotrophic lateral sclerosis (ALS), a motor neuron disease clinically characterized by progressive muscle weakness, muscular atrophy, fasciculations and spasticity ([@awv358-B23]). Also common neuropathological findings and genetic causes suggest that FTD and ALS are two extremes of a continuum of neurodegenerative disorders. Both ALS and FTD have pathological subgroups characterized by inclusions of the TDP-43 or FUS proteins ([@awv358-B38]). Genetically, *C9orf72* repeat expansions are the most common cause of FTD and ALS, explaining 25% of familial FTD and 37% of familial ALS patients ([@awv358-B27]). Up to 88% of familial patients with FTD and ALS (FTD-ALS) are explained by the *C9orf72* repeat expansion ([@awv358-B11])*.*

Most recently, TANK-binding kinase 1 (*TBK1*) was identified as a gene for ALS and FTD in which loss of function mutations result in 50% loss of TBK1 protein ([@awv358-B7]; [@awv358-B14]; [@awv358-B17]; [@awv358-B31]). TBK1 is an important serine/threonine kinase of the IκB kinase family. It phosphorylates a wide range of substrates, including optineurin (*OPTN*) ([@awv358-B19]; [@awv358-B40]) and p62 (*SQSTM1*), two proteins involved in autophagy and associated with FTD and ALS ([@awv358-B28]; [@awv358-B13]; [@awv358-B35]; [@awv358-B37]). These findings emphasized once more a major role of defective autophagy in neurodegeneration ([@awv358-B29]).

We sequenced the coding sequence of *TBK1* in a Belgian cohort of 481 unrelated FTD and FTD-ALS patients, and 147 ALS patients, and identified 10 patients carrying a loss of function mutation. The overall *TBK1* loss of function mutation frequency in the Belgian FTD and ALS patient cohort was 1.7%, of which 1.1% in FTD, 4.5% in FTD-ALS and 3.4% in ALS patients. This made *TBK1* loss of function mutations the third most frequent cause of FTD and the second most frequent cause of ALS in the Belgian patient cohorts ([@awv358-B17]). One loss of function mutation, p.Glu643del, segregated in an extended FTD-ALS family, DR158 ([Fig. 1](#awv358-F1){ref-type="fig"}A). In two *TBK1* carriers, brain and spinal cord was investigated and the pathological diagnosis was TDP type B ([@awv358-B17]). Here, we describe the clinical characteristics of *TBK1* carriers with FTD or ALS. We also compared the genotype--phenotype data of FTD patients with a *TBK1* mutation with those of FTD patients with a causal mutation in *GRN* or *C9orf72*, two other genes implicated in FTLD TDP-43 ([@awv358-B36]), and those of 259 patients with FTD without identified mutations. With the current study we aimed to discover specific clinical characteristics which can suggest the presence of a *TBK1* mutation. In particular for patients with (a familial history of) both FTD and ALS, specific clinical characteristics could help in a clinically based differentiation with *C9orf72* carriers.

![**Families segregating the *TBK1* mutation p.Glu643del**. (**A**) DR158 pedigree; (**B**) DR663 pedigree. To protect the privacy of the family members, the gender of each person was masked, the order of sibs was scrambled and the number (*n*) of tested at-risk individuals shown in white diamonds was not specified. Filled symbols are clinically affected patients with their age at onset (AAO) in years (y) below the symbol. Age at death (AAD) is shown for individuals who died at old age without symptoms. Age at last evaluation (AALE) is shown for currently unaffected mutation carriers that are still alive. An asterisk identifies the family members of whom genomic DNA was available and a 'c' identifies the *TBK1* p.Glu643del mutation carriers. A '+' sign indicates which DR663 members are carriers of the *C9orf72* repeat expansion. The arrow identifies the proband of the family. Only the clinically affected patients known to carry the mutation and of whom clinical records were available, were described in this paper. Other family members pictured as clinically affected were not described because the clinically affected state was only based on oral information obtained from relatives or because their mutation status was not known. (**C**) Liability risk curve for TBK1 loss of function (LOF) mutation carriers. This curve shows the proportion (%) of *TBK1* loss of function mutation carriers (*y*-axis) that is affected at a certain age (years) (*x*-axis). The crosses stand for censoring of the patients that are clinically still unaffected at the last time of clinical evaluation or at death. The crosses are placed on the curve at the age of last evaluation or at the age of death.](awv358f1p){#awv358-F1}

Materials and methods
=====================

Patients and relatives
----------------------

The FTD, FTD-ALS and ALS patients were part of larger cohorts recruited since 1998 by neurologists of different university and general hospitals nationwide, collaborating in the framework of the Belgian Neurology (BELNEU) consortium. Index patients were evaluated using a standard protocol, which included a detailed clinical and family history, clinical neurological examination, neuropsychological testing, biochemical analyses, and neuroimaging. The diagnosis of possible or probable FTD was made according to the international consensus criteria ([@awv358-B21]; [@awv358-B33])*.* Patients with a combination of the behavioural and the language variant of FTD at presentation were denoted as mixed FTD. Diagnosis of FTD-ALS was made in patients with FTD who also met the criteria for clinical possible or probable ALS according to the revised El Escorial criteria ([@awv358-B5]; [@awv358-B12])*.* Autopsy and neuropathological examinations had been performed for two *TBK1* carriers. Additional relatives of mutation carriers for whom detailed neurological records were available were included in the current study. All data records, medical records, neuroimaging studies, and autopsy reports were reviewed, and the demographic, clinical and pathological characteristics of each patient were summarized in a standardized format. Among relatives of Family DR158, segregating the *TBK1* p.Glu643del mutation, there were two affected relatives of the index patient with FTD-ALS who were diagnosed with dementia unspecified ([@awv358-B17]). These patients with unspecified dementia were combined with the group of FTD/FTD-ALS patients in the clinical studies of *TBK1*. More detailed information on the clinical evaluation and technical investigations can be found in the [Supplementary material](#sup1){ref-type="supplementary-material"}.

For molecular genetic studies, index patients and their relatives were contacted by trained research nurses. Detailed information on family history of dementia and/or ALS was gathered, and additional patients and unaffected family members were asked to participate in genetic studies. A positive family history was defined as the occurrence of at least one affected relative with dementia or motor neuron disease. Criteria for autosomal dominant inheritance were defined as the occurrence of at least three affected individuals with dementia or motor neuron disease in the pedigree in two or more generations. Written informed consent for participation in the clinical and genetic studies, and for brain autopsy when appropriate, was obtained from participants and/or from their legal guardians. The clinical study protocol and the informed consent forms for patient ascertainment were approved by the local ethics committees of each of the collaborating neurological centres. The genetic and pathological study protocols and informed consent forms were approved by the Ethics committee of the University Hospital of Antwerp and the University of Antwerp, Belgium.

Molecular genetic analysis
--------------------------

The coding region of *TBK1* was sequenced using massive parallel sequencing as described in the [Supplementary material](#sup1){ref-type="supplementary-material"} and in [@awv358-B17]. All carriers of a repeat expansion mutation in *C9orf72* or a loss of function mutation in *GRN* ([@awv358-B9]), were included in the current genotype--phenotype correlation study performed in the Belgian FTD and FTD-ALS cohort. *C9orf72* repeat expansion testing was performed by repeat-primed PCR, as described ([@awv358-B16]). *GRN* loss of function mutations were detected using Sanger sequencing or next-generation sequencing. Data of affected relatives of index patients were included if they or their offspring carried the mutation. The genetic and clinical characteristics of the *C9orf72* and *GRN* carriers are summarized in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. The mutation-negative FTD patients (*n* = 259) were analysed for mutations in *GRN*, *C9orf72*, *MAPT* and *VCP*, as well as for 10 other Mendelian genes associated with other major neurodegenerative brain diseases, i.e. Alzheimer's disease, prion disease, ALS and Parkinson's disease (*APP*, *PSEN1*, *PSEN2*, *PRNP*, *TARDBP*, *FUS*, *SOD1*, *LRRK2*, *PARK2*, *SNCA*). The genetic profiling of the known genes was performed by use of a next-generation sequencing gene panel based on high-level multiplex PCR amplification of targeted exons using the Multiplex Amplification of Specific Targets for Resequencing (MASTR) technology ([www.multiplicom.com](http://www.multiplicom.com)), followed by sequencing on a MiSeq platform (Illumina). The non-mutation carriers in this paper were also negative for the *C9orf72* repeat expansion and *TBK1* loss of function mutations.

Statistical analysis
--------------------

Average onset age and average disease duration were compared between ALS and FTD patients carrying a *TBK1* mutation, using a Mann-Whitney U-test because of the small sample group. Comparison of average onset age and average disease duration between carriers of a mutation in one of the three genes (*TBK1*, *C9orf72 or GRN*), or non-mutation carriers, was performed using the non-parametric Kruskal Wallis test and Mann-Whitney U-test because onset age and disease duration were not normally distributed in all groups (Shapiro-Wilk test) and because of the small group of *TBK1* mutation carriers. Clinical characteristics were compared using a Fisher exact test. All tests were two-tailed and the level of significance was set at *P* \< 0.05.

Results
=======

Demographic characteristics
---------------------------

Demographic, genetic and clinical data of all *TBK1* carriers diagnosed with FTD, FTD-ALS or ALS are summarized in [Table 1](#awv358-T1){ref-type="table"}. The mean age at onset of *TBK1* carriers was 62.1 ± 8.9 years (range 41--73) with a mean disease duration of 4.7 ± 4.5 years (range 1--13). Three *TBK1* carriers also had a *C9orf72* repeat expansion: Patient DR1044 and two members of Family DR663 ([Fig. 1](#awv358-F1){ref-type="fig"}B and [Table 1](#awv358-T1){ref-type="table"}). When excluding these three double mutation carriers, the mean onset age of *TBK1* carriers was 64.5 ± 6.7 years (range 48--73) and the mean disease duration 5.7 ± 4.8 years (range 1--13). Patients with ALS, including the three *C9orf72* carriers, had an earlier mean age at onset (58.1 ± 9.4 years) than patients with FTD (65.5 ± 8.0 years) and a shorter mean disease duration (1.7 ± 1.0 years and 7.1 ± 4.8 years, respectively), almost reaching the level of significance (*P* = 0.054 and *P* = 0.052, respectively). However, when we excluded the three *C9orf72* repeat expansion carriers, the difference in onset age was much smaller (65.5 ± 8.0 years in FTD versus 63.0 ± 4.5 years in ALS) (*P* = 0.214). The disease duration was still much shorter in ALS patients than FTD patients (1.6 ± 1.3 years and 7.1 ± 4.8 years' respectively), but not significantly (*P* = 0.143).

###### 

Genetic, demographic and clinical data of *TBK1* loss of function mutation carriers

  *TBK1* mutation                                                                         Patients/relatives[^a^](#awv358-TF1){ref-type="table-fn"}   Gender   Familial history   Age at onset, y   Age at death, y   Disease duration, years   Clinical diagnosis    Diagnosis subtype   
  --------------------------------------------------------------------------------------- ----------------------------------------------------------- -------- ------------------ ----------------- ----------------- ------------------------- --------------------- ------------------- --------------
  p.Glu643del c.1927_1929delGAA                                                           DR158                                                       III.1    Male               F-AD              69                72                        3                     ALS                 Spinal onset
  III.2                                                                                   Male                                                        F-AD     69                 75                6                 FTD                       BvFTD                                     
  III.3                                                                                   Male                                                        F-AD     70                 73                3                 D                                                                   
  III.6                                                                                   Female                                                      F-AD     61                 74                13                FTD                       BvFTD                                     
  III.8[^b^](#awv358-TF2){ref-type="table-fn"}                                            Female                                                      F-AD     62                 74                11                FTD-ALS                   BvFTD, spinal onset                       
  III.9                                                                                   Female                                                      F-AD     73                 84                11                D                                                                   
  DR467                                                                                   Female                                                      F        64                                   \> 9              FTD                       BvFTD                                     
  DR663                                                                                   II.1[^c^](#awv358-TF3){ref-type="table-fn"}                 Male     F-AD               51                53                2                         ALS                   Bulbar onset        
  II.2[^b^](#awv358-TF2){ref-type="table-fn"}^,^[^c^](#awv358-TF3){ref-type="table-fn"}   Male                                                        F-AD     41                 41                \< 1              ALS                       Bulbar onset                              
  DR1044[^c^](#awv358-TF3){ref-type="table-fn"}                                           Male                                                        S        63                 66                3                 ALS                       Unknown                                   
  DR1121                                                                                  Male                                                        F        70                                   \> 6              FTD                       PPA                                       
  DR1122                                                                                  Female                                                      S        69                                   \> 7              FTD                       BvFTD                                     
  p.Gly272_Thr331del c.992+1G\>T                                                          DR189[^d^](#awv358-TF4){ref-type="table-fn"}                Male     F                  48                50                2                         FTD                   BvFTD               
  p.Ser398Profs\*11 c.1192delT                                                            DR1123                                                      Male     F                  59                                  \> 5                      ALS                   Bulbar onset        
  p.Ser518Leufs\*32 c.1551_1552insTT                                                      DR1124[^d^](#awv358-TF4){ref-type="table-fn"}               Female   U                  64                64                \< 1                      ALS                   Bulbar onset        
  p.Asp167del c.499_501delGAT                                                             DR1127                                                      Male     S                  60                61                1                         ALS                   Unknown             

^a^Roman numbers indicate affected relatives in Families DR158 and DR663 ([Fig. 1](#awv358-F1){ref-type="fig"}).

^b^Patient III.8 is the proband of Family DR158, Patient II.2 of Family DR663.

^c^Carriers of a *C9orf72* repeat expansion mutation.

^d^Patients with a pathological diagnosis of TDP-43 proteinopathy.

D = dementia unspecified; F = familial; F-AD = familial-autosomal dominant; S = sporadic.

cDNA is numbering based on NM_013254.3.

A liability risk curve based on onset age or age at last clinical evaluation of *TBK1* carriers and relatives (*n* = 34; 18 affected, 16 unaffected), showed that 50% of the *TBK1* carriers were affected by the age of 70 ([Fig. 1](#awv358-F1){ref-type="fig"}C). Conversely, four *TBK1* carriers were still unaffected at ages of 73, 79, 81 and 82 years. Six carriers were members of the same family, Family DR158, in which the *TBK1* mutation, p.Glu643del, co-segregates with disease ([@awv358-B17]) ([Fig. 1](#awv358-F1){ref-type="fig"}A). In Families DR158 and DR663 ([Fig. 1](#awv358-F1){ref-type="fig"}B), the segregation pattern was compatible with autosomal dominant inheritance. Further, four index patients had at least one affected relative with dementia or motor neuron disease, but the criteria we used for autosomal dominant inheritance were not met*.* Three index patients did not have a documented familial history of neurodegenerative diseases, and for one index patient we had no information.

Behavioural, language and cognitive dysfunction
-----------------------------------------------

Of the *TBK1* carriers, five had behavioural variant FTD, one PPA, one behavioural variant FTD plus ALS and two unspecified dementia*.* Details on their behavioural, cognitive, and clinical characteristics are shown in [Table 2](#awv358-T2){ref-type="table"}. In the patients with behavioural variant FTD, behavioural disinhibition and social inappropriate behaviour was present in more patients than apathy, especially in the early disease stage. However, some patients such as Patients DR189 and III.2 in Family DR158, presented concomitantly with apathy or passivity as well as elements of disinhibition such as aggressiveness and inappropriate laughing. Aggressive behaviour and motor agitation with runaway behaviour were frequent in *TBK1* carriers. Also echolalia and perseverations were quite common in these patients. Visual hallucinations were present in one patient of Family DR158 (Patient III.6).

###### 

Detailed behavioural, cognitive and clinical characteristics of *TBK1* carriers

  Patients/relatives[^a^](#awv358-TF7){ref-type="table-fn"}   A                                             BD    C/S   HO   MoA   RM   ED   OA/A   PP   EoS   CD   IR   SP   WR   ML   PA   OD   AP   PS   H    FRS   T    BK/HK   R    S    HR   BS   F    MuA   LP    DPh   DA    DP   
  ----------------------------------------------------------- --------------------------------------------- ----- ----- ---- ----- ---- ---- ------ ---- ----- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----- ---- ------- ---- ---- ---- ---- ---- ----- ----- ----- ----- ---- --
  DR158                                                       III.1                                                                                                                                         \+              \+      \+             \+   \+   \+    \+    \+    +\*        
  III.2                                                       \+                                            \+    \+         \+    \+   \+                                    \+   \+        \+   \+   \+                           \+                                                    
  III.3                                                       \+                                                                                                              \+   \+        \+        \+        \+                      \+   \+   \+              \+                     
  III.6                                                       +\*                                           \+               \+                                               \+   \+                  \+   \+                           \+        \+                    \+               
  III.8[^b^](#awv358-TF8){ref-type="table-fn"}                                                              \+    \+                                     +\*                       \+                  \+                                \+   \+   \+              \+          \+         
  III.9                                                       \+                                                        \+   \+         \+               \+                        \+        \+   \+   \+                                                                                 
  DR467                                                       +\*                                           \+    \+    \+   \+         \+                                    \+   \+        \+        \+                   \+      \+                                                    
  DR663                                                       II.1[^c^](#awv358-TF9){ref-type="table-fn"}                                                                                                                                                    +\*   +\*         \+    \+   
  DR1121                                                      \+                                                                                         \+    \+        \+   \+   \+        \+                        \+           \+                                                    
  DR1122                                                      +\*                                           \+    \+    \+   \+    \+   \+               \+         \+        \+   \+                                               \+        \+                                          
  DR189[^d^](#awv358-TF10){ref-type="table-fn"}               \+                                            +\*   \+    \+   \+    \+                                                   \+                       \+                                                      +\*              
  DR1123                                                                                                                                                                                                                                 \+   \+   \+   \+   \+    +\*   \+    \+    \+   
  DR1124[^d^](#awv358-TF10){ref-type="table-fn"}                                                            \+    \+                                                               \+                                                         \+        \+   \+    \+    \+    \+         

^a^Roman numbers indicate affected relatives in Families DR158 and DR663 ([Fig. 1](#awv358-F1){ref-type="fig"}).

^b^Patient III.8 is the proband of Family DR158.

^c^Carrier of a C9orf72 repeat expansion mutation.

^d^Patients with a pathological diagnosis of TDP-43 proteinopathy.

A = apathy; AP = apraxia; BD = behavioural disinhibition; BK/HK = brady/hypokinesia; BS = Babinski sign; C/S = compulsive or stereotyped; CD = comprehension deficits; DA = dysartria; DP = dyspnoea; DPh = dysphagia; ED = executive dysfunctions; EoS = economy of speech; F = fasciculations; FRS = frontal release signs; H = hallucinations; HO = hyperorality; HR = hyperreflexia; IR = impaired repeating; LP = limb paresis; ML = memory loss; MoA = motor agitation; MuA = muscle atrophy; OA/A = oral apraxia or agrammatism; OD = orientation difficulties; PA = prosopagnosia; PP = phonetic paraphasia; PS = psychiatric symptoms; R = rigidity; RM = repetitive movements; S = spasticity; SP = semantic paraphasia; T = tremor; WR = word retrieval difficulties. Asterisk indicates feature appeared later in the disease.

PPA Patient DR1121 had a clinical picture characterized by an important reduction in spontaneous speech with severe difficulties in word retrieval. No clear comprehension problems were reported in hetero-anamnesis, although he scored 0/3 on the ACE-R (Addenbrooke's Cognitive Examination-Revised) word comprehension test. He produced some semantic paraphasias. No oral apraxia was present. The patient became more apathetic and passive, and developed severe problems in short-term memory. Five other patients with behavioural variant FTD or patients with unspecified dementia also suffered from word retrieval difficulties. Furthermore, one behavioural variant FTD carrier, Patient DR1122, exhibited impaired repeating of function words as well as an important reduction of spontaneous speech later in the evolution of the disease. This last feature was also present in two patients of Family DR158: the patient with FTD-ALS (Patient III.8) and a patient with unspecified dementia (Patient III.9). This latter patient was also known to have alcoholism. Initially, this patient had especially anterograde memory deficits as well as mild visuoconstructive apraxia. A clinical diagnosis of Korsakoff dementia was considered. During follow-up, the patient developed a more global cognitive deterioration with deficits in short-term memory, executive dysfunctions and behavioural disturbances including apathy and hyperorality. As the patient initially presented with early prominent memory difficulties, the criteria for FTD ([@awv358-B33]) were not met, although the clinical evolution was suggestive of FTD. The alcohol abuse can be considered as an early behavioural change that might have been related to FTD as it only occurred during the 5 years before disease onset. The other patient in Family DR158 with unspecified dementia (Patient III.3) was previously (at the age of 47) diagnosed with multiple sclerosis. The first reported cognitive problems consisted of progressive short-term memory problems, disorientation, apathy and episodes of confusion. These cognitive problems were attributed to further progression of multiple sclerosis and no detailed neuropsychological examination was performed.

Memory and encoding difficulties were remarkably present in *TBK1* carriers: seven of eight patients with FTD or unspecified dementia, one patient with ALS and the FTD-ALS patient, had complaints of episodic memory loss relatively early in the disease. Also disorientation in time and/or space was present in five patients. Because of the occurrence of an early amnestic syndrome, one patient, Patient DR1122, received initially a diagnosis of amnestic mild cognitive impairment, and another patient (Patient III.2) in Family DR158, was diagnosed with Alzheimer's disease. In this last patient, doubt persisted in the differential diagnosis between the frontal variant of Alzheimer's disease and FTD. However, all patients with FTD also developed important behavioural problems early in the disease.

One patient, Patient DR1124, who was eventually diagnosed with bulbar ALS, presented initially with memory problems and a score of 24/30 on MMSE (Mini-Mental State Examination). The patient also exhibited signs of behavioural disinhibition and impulsivity. However, this patient soon developed a rapidly progressive form of bulbar ALS that overruled the cognitive symptoms and no further diagnostic workup was performed concerning cognition.

Psychiatric symptoms were present in seven *TBK1* carriers: six of nine patients with FTD, FTD-ALS or unspecified dementia and one ALS patient. Six of these patients were members of Family DR158. In this family, we observed a very high load of psychiatric diseases (relapsing depressions, alcohol abuse, bipolarity and schizophrenia) in *TBK1* carriers as well as non-mutation carriers.

Motor neuron disease and extrapyramidal symptoms
------------------------------------------------

Seven *TBK1* carriers had a diagnosis of pure ALS and one a diagnosis of co-occurring ALS and FTD. Four ALS patients had a bulbar onset and two a spinal onset, and of two we had no records or information on the site of onset. We had detailed clinical information of five ALS patients. The index patient of the Family DR158 (Patient III.8) presented with initial symptoms of progressive gait problems, aggressive behaviour and reduced spontaneous speech. Signs of upper motor neuron disease as hyperreflexia and spasticity, especially of the right leg and the left arm, were most prominent at presentation. The re-evaluation 7 years post-diagnosis, in which the patient had not been followed by a neurologist, revealed a totally mute patient, bed-ridden in decorticate posture with gastrostomy tube. Further, Patients DR1123 and DR1124 had most prominent upper motor neuron signs. Patient DR1123 initially presented with bulbar dysarthria, and later, progressive gait disturbances appeared and fine motor skills decreased. One and a half years after disease onset, he developed important respiratory weakness with need for BiPAP (bilevel positive airway pressure) and dysphagia with placement of PEG (percutaneous endoscopic gastrostomy). Discrete muscle atrophy was present. After 3.5 years he had developed quadriparesis with spasticity and hyperreflexia. Patient DR1124 developed severe bulbar speech with important bulbar affect lability, over a period of 8 weeks. Discrete atrophy of the tongue with fasciculations was present. The patient was diagnosed with a rapidly progressive ALS and developed a spastic quadriparesis over a period of only 3 months. In contrast, Patient II.1 of Family DR663 did not present with any pyramidal signs. His first complaints consisted of dysarthria and dysphagia. First, the diagnosis of myasthenia gravis was assumed and a beneficiary effect of pyridostigmine treatment on the dysphagia was noted. During follow-up, the patient developed slight limb muscle atrophy. Patient III.1 of Family DR158 had clear upper motor neuron as well as lower motor neuron signs. The patient presented with gait disturbances, balance problems and extrapyramidal symptoms (poker face, hypokinesia and positional tremor). Subsequently, he rapidly developed limb paresis, fasciculations, muscle atrophy and hyperreflexia.

One patient with FTD (Patient III.6) of Family DR158 displayed hypertonia of the left hemicorpus with Babinski sign on the left side and a central left facial nerve paresis. These clinical symptoms were hypothesized to be related to the pronounced right frontal lobe atrophy on brain MRI. Patient III.3 of Family DR158 had a diagnosis of multiple sclerosis since the age of 47. He exhibited paresis of the lower limbs with spasticity, hyperreflexia and Babinski signs, which were attributed to his diagnosis of secondary progressive multiple sclerosis. Later in the disease he developed paresis and spasticity of the upper limbs as well.

In four patients with FTD and one patient with ALS, extrapyramidal symptoms were reported. In all FTD patients rigidity was present, one also exhibited bradykinesia and another, a resting tremor. The patient with ALS presented with positional tremor and bradykinesia. All patients with extrapyramidal symptoms were carriers of the *TBK1* p.Glu643del mutation.

Technical investigation findings
--------------------------------

Records of performed structural imaging were available for all *TBK1* carriers with a clinical diagnosis of FTD or FTD-ALS, two patients with unspecified dementia and two patients with ALS ([Table 3](#awv358-T3){ref-type="table"}). Various patterns of atrophy were observed on visual inspection. When atrophy was localized, the temporal region was most frequently involved. Asymmetric atrophy was seen in five patients. In four, the right hemisphere was more severely affected than the left hemisphere. On the MRI images in Patient III.3 of Family DR158, demyelinating lesions were present at the semioval centre, in the periventricular regions and infratentorial at the level of the brainstem, compatible with his diagnosis of multiple sclerosis.

###### 

Imaging findings in *TBK1* carriers

  Patients/relatives[^a^](#awv358-TF12){ref-type="table-fn"}   Structural imaging                             Functional imaging(FDG PET/SPECT)                
  ------------------------------------------------------------ ---------------------------------------------- ----------------------------------- ------------ -----------------------
  DR158                                                        III.1                                          No clear atrophy                                 
  III.2                                                        H, O \> G (incl. C)                            R \> L                                           
  III.3                                                        FR                                             BI                                               
  III.6                                                        T \> G (incl. C)                               \(T\) R \> L                                     
  III.8[^b^](#awv358-TF13){ref-type="table-fn"}                T, C                                           \(T\) R \> L                                     
  III.9                                                        G                                              BI                                               
  DR467                                                        H, T                                           \(T\) R \> L                                     
  DR663                                                        II.1[^c^](#awv358-TF14){ref-type="table-fn"}                                                    
  DR1121                                                       FR, T \> G                                     L \> R                              FR, T \> P   L \> R
  DR1122                                                       No clear atrophy                               FR, T \> P                          L \> R       
  DR189[^d^](#awv358-TF15){ref-type="table-fn"}                T \> FR, P                                     BI                                  FR, T, P     (FR, P) BI R \> L (T)
  DR1123                                                                                                                                                       
  DR1124[^d^](#awv358-TF15){ref-type="table-fn"}               T, H                                           BI                                               

^a^Roman numbers indicate affected relatives in Families DR158 and DR663 ([Fig. 1](#awv358-F1){ref-type="fig"}).

^b^Patient III.8 is the proband of Family DR158 .

^c^Carrier of a *C9orf72* repeat expansion mutation.

^d^Patients with a neuropathological diagnosis of TDP-43 proteinopathy.

BI = bilateral; C = cerebellar; FDG = fluorodeoxyglucose; FR = frontal; G = global; H = hippocampal; L = left; O = occipital; P = parietal; R = right; SPECT = single-photon emission computed tomography; T = temporal.

Functional imaging was performed in three *TBK1* carriers with a FTD diagnosis, consisting of single-photon emission computed tomography (SPECT) in one patient and PET with ^18^F-fluorodeoxyglucose (FDG-PET) in two patients. In all, predominant hypoperfusion or glucose hypometabolism was seen in the frontal and temporal regions. The parietal regions were also involved, but to a lesser extent. Also, in all, the pattern of hypoperfusion or glucose hypometabolism was asymmetric. In two patients, the left side was more severely affected and in one patient the right side. FDG-PET images of the two patients with predominant left side involvement (Patients DR1121 and DR1122) are illustrated in [Fig. 2](#awv358-F2){ref-type="fig"}. Both patients displayed a similar pattern of frontal, anterior and medial temporal and, to a lesser extent, parietal hypometabolism. However, the pattern was less extended in Patient DR1121, who was clinically diagnosed with PPA. The other patient, Patient DR1122, clinically diagnosed with behavioural variant FTD, also exhibited language difficulties such as word retrieval difficulties, impaired repeating and loss of spontaneous speech. In Patient DR1122, amyloid PET imaging was also performed, which was not compatible with Alzheimer's disease. Lumbar puncture with evaluation of the levels of β-amyloid, total tau and phospho-tau~181P~ in CSF was performed in three *TBK1* carriers with FTD. In all three, the CSF biomarkers profile was not compatible with Alzheimer's disease. In one, there was an isolated increased total tau.

![**Neuroimaging using FDG-PET.** These images are *z*-map renderings of the FDG-PET in Patients DR1121 and DR1122. The *z*-maps are calculated by comparing the individual glucose metabolic pattern to the normal age-matched control. Both imaging series show a similar pattern of remarkable asymmetry with a severely decreased metabolism in the left frontal, and anterior and medial temporal lobe. These results are much more asymmetric than age could explain, do not follow typical age-related patterns, and are much more intense.](awv358f2p){#awv358-F2}

We had detailed information on EMG investigations in five *TBK1* carriers with ALS. In three, chronic denervation signs such as giant potentials and reduced interference patterns were reported. In one, active denervation signs and fasciculations were also observed. Remarkably, EMG in Patients DR1123 and DR1124 did not show obvious neurogenic changes, compatible with their clinical presentation of predominantly upper motor neuron signs.

Neuropathology
--------------

The clinical diagnosis of FTD was autopsy-confirmed in one *TBK1* carrier, Patient DR189. Macroscopically, there was a mild atrophy of the frontal cortices and to a lesser extent of the temporal neocortex ([Fig. 3](#awv358-F3){ref-type="fig"}A). Furthermore, mild hippocampal atrophy was present. Microscopically, a moderate number of TDP-43 neuronal cytoplasmic inclusions and short dystrophic neurites were detected throughout all layers of the frontal and temporal neocortices, in the hippocampal dentate gyrus, the parahippocampal transentorhinal cortex, the neostriatum and the pallidum \[[Fig. 3](#awv358-F3){ref-type="fig"}B(i and ii)\]. No neuronal intranuclear inclusions were observed. In the internal capsule, a moderate amount of glial cytoplasmic inclusions were present. These lesions stained positive for p62 \[[Fig. 3](#awv358-F3){ref-type="fig"}B(iv and v)\], and to a lesser extent for ubiquitin. These findings were compatible with FTLD TDP type B proteinopathy ([@awv358-B25]).

![**Neuropathology.** (**A**) Macroscopy Patient DR189. Macroscopic picture of the right cerebral and cerebellar hemisphere of Patient DR189, from a lateral view (**i**) and a medial view (**ii**). (**B**) TDP-43 and p62 immunohistochemistry. Staining for TDP-43 and p62 of the frontal cortex (**i** and **iv**) and the hippocampus (**ii** and **v**) of FTLD Patient DR189 and for the spinal cord of ALS Patient DR1124 (**iii** and **vi**). TDP-43 and p62 positive neuronal cytoplasmic inclusions are indicated with an arrow. (**C**) AT8 staining of the hippocampus and parahippocampal gyrus DR1124. AT8 staining showed many neuronal cytoplasmic inclusions in the dentate gyrus of the hippocampus (**i**). In the parahippocampal cortex, neuronal neurofibrillary tangles or neuronal cytoplasmic inclusions were found (arrow, **ii**), whereas in the white matter, glial astrocytic cytoplasmic inclusions (arrowhead, **iii** and **iv**) and tufted astrocytes (double arrow, **iv**) were present.](awv358f3p){#awv358-F3}

In Patient DR1124, the diagnosis of ALS was autopsy-confirmed. Macroscopically, mild cortical frontal and mild hippocampal atrophy was noted. Pathological signs of lower motor neuron disease were present, manifesting as neuronal loss in the hypoglossal nucleus as well as in the ventral horns of the cervical and thoracic spinal cord. Additionally, loss of Betz cells and severe demyelination of the pyramidal tract in mesencephalon, pons, medulla oblongata and the entire spinal cord confirmed the presence of upper motor neuron disease. The TDP-43- and p62-positive neuronal cytoplasmic inclusions were mainly restricted to the lower motor neurons, i.e. the hypoglossal nucleus and the ventral horn neurons of cervical and thoraco-lumbar spinal cord \[[Fig. 3](#awv358-F3){ref-type="fig"}B(iii--vi)\]. The findings of TDP-43 staining in the cortex were most suggestive for TDP type B proteinopathy. Besides the TDP-43 pathology, a moderate amount of AT8-immunoreactive tufted astrocytes and 'neurofibrillary tangle'-like neuronal cytoplasmic inclusions was found in the frontal and temporal neocortex ([Fig. 3](#awv358-F3){ref-type="fig"}C). More technical details on the performed neuropathological investigations can be found in the [Supplementary material](#sup1){ref-type="supplementary-material"}.

Genotype--phenotype correlations in patients with FTD
-----------------------------------------------------

Demographic and clinical data of the seven *TBK1* carriers with FTD were compared to 65 *C9orf72* carriers, 52 *GRN* carriers and 259 non-mutation carriers ([Table 4](#awv358-T4){ref-type="table"})*.* The mean onset age in the *TBK1* carriers was 63.3 ± 7.7 years, whereas *C9orf72* carriers were significantly younger at disease onset (54.3 ± 9.2 years, *P* = 0.019) ([Fig. 4](#awv358-F4){ref-type="fig"}A). When only taking into account the index patients, the significance remained (*P* = 0.049). The mean disease duration of *TBK1* carriers was relatively long (8.2 ± 4.9 years), but not significantly different than that of the other patient groups.

![**Genotype--phenotype correlations in FTD patients.** In these graphs, FTD patients are divided in groups based on their causal gene mutation, i.e. *TBK1*, *C9orf72* and *GRN* carriers and non-mutation carriers. The latter group is further divided by familial history in familial and sporadic, and patients with unknown familial history. (**A**) Ages at onset. The boxplots illustrate the distribution of ages at onset in each FTD patient group. For each genetic subtype a boxplot is created in which the middle horizontal line represents the median age at onset. The upper and lower border of the box represent the value of the first quartile (25%) and the third quartile (75%) of the data. The whiskers represent the minimal and maximal age at onset with exception of the outliers. The outliers are presented as circles and refer to ages at onset that are greater than 1.5 interquartile ranges away from the 25th or the 75th percentile. (**B**) Subtype of behavioural FTD. This bar graph illustrates which proportion of the behavioural variant FTD patients of each patient group has frontal disinhibition or apathy as predominant feature, respectively. (**C**) Presence of extrapyramidal symptoms. In this bar graph, the proportion of patients who exhibit extrapyramidal symptoms are pictured for each patient group. (**D**) Psychiatric symptoms. This bar graph shows the proportion of FTD patients with psychiatric symptoms for each patient group. The bars are subdivided for the proportion of the major psychiatric characteristic.](awv358f4p){#awv358-F4}

###### 

Demographic and clinical characteristics of *TBK1* carriers versus *C9orf72*, *GRN* or non-mutation carriers

                                                                            *TBK1*        *C9orf72*     *GRN*         No mutation                               
  ------------------------------------------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  FTD patients (index), *n*                                                 7 (5)         65 (51)       52 (21)       76 (76)       102 (102)     81 (81)       
  Male, *n* (%)                                                             3 (42.9)      36 (55.4)     23 (44.2)     44 (57.9)     57 (55.9)     48 (59.3)     
  Age at onset, y                                                           Mean (SD)     63.3 (7.7)    54.3 (9.2)    61.0 (6.5)    63.9 (9.2)    61.7 (11.0)   68.5 (11.4)
  Median (range)                                                            64 (48--70)   54 (29--75)   62 (45--70)   65 (29--79)   63 (29--83)   72 (42--82)   
  Disease duration, y                                                       Mean (SD)     8.2 (4.9)     6.0 (4.8)     5.6 (2.1)     6.0 (3.14)    7.1 (4.2)     8.8 (3.0)
  Median (range)                                                            8.7 (2--13)   4.7 (1--19)   5.4 (2--11)   6.0 (1--14)   7.0 (1--22)   9.0 (5--12)   
  Familial history, *n* (%)                                                 F-AD          3 (42.9)      35 (53.8)     18 (34.6)     15 (19.7)                   
  F                                                                         3 (42.9)      21 (32.3)     16 (30.8)     61 (80.3)                                 
  S                                                                         1 (14.3)      3 (4.6)       5 (9.6)                     102 (100.0)                 
  U                                                                         0             6 (9.2)       13 (25.0)                                 81 (100.0)    
  Clinical subtype, *n* (%[\*](#awv358-TF18){ref-type="table-fn"})          BvFTD         6 (85.7)      51 (83.6)     19 (45.2)     41 (63.1)     62 (67.4)     19 (65.5)
  PNFA                                                                      0             5 (8.2)       16 (38.1)     5 (7.7)       13 (14.1)     4 (13.8)      
  SD                                                                        1 (14.3)      3 (4.9)       4 (9.5)       14 (21.5)     7 (7.6)       4 (13.8)      
  LA                                                                        0             0             0             0             2 (2.2)       0             
  PPA U                                                                     0             0             0             1 (1.5)       0             0             
  Mixed FTD                                                                 0             2 (3.3)       3 (7.1)       4 (6.2)       8 (8.7)       2 (6.9)       
  Behavioural subtype, *n* (%[\*](#awv358-TF18){ref-type="table-fn"})       Apathetic     1 (16.7)      14 (31.1)     14 (87.5)     13 (36.1)     25 (41.7)     6 (66.7)
  Disinhibition                                                             5 (83.3)      31 (68.9)     2 (12.5)      23 (63.9)     35 (58.3)     3 (33.3)      
  FTD-ALS , *n* (%[\*](#awv358-TF18){ref-type="table-fn"})                  Total         1 (14.3)      15 (23.1)     0             1 (1.3)       5 (4.9)       3 (3.7)
  Bulbar onset                                                              0             3 (4.6)       0             0             1 (1.0)       1 (1.2)       
  Spinal onset                                                              1 (14.3)      3 (4.6)       0             1 (1.3)       0             0             
  Bulbospinal onset                                                         0             5 (7.7)       0             0             3 (2.9)       0             
  Unknown onset                                                             0             4 (6.2)       0             0             1 (1.0)       2 (2.5)       
  Extrapyramidal symptoms, *n* (%[\*](#awv358-TF18){ref-type="table-fn"})   4 (57.1)      9 (17.6)      7 (18.9)      22 (33.3)     24 (27.9)     10 (37.0)     
  Psychiatric symptoms, *n* (%[\*](#awv358-TF18){ref-type="table-fn"})      Total         4 (57.1)      16 (30.7)     7 (18.9)      15 (24.6)     28 (33.3)     5 (25.0)
  Psychosis                                                                 2 (28.6)      8 (15.3)      2 (5.4)       4 (6.6)       12 (14.3)     2 (10.0)      
  Depression                                                                2 (28.6)      7 (13.4)      5 (13.5)      7 (11.5)      14 (16.7)     3 (15.0)      
  Abuse                                                                     0             4 (7.7)       0             4 (6.6)       4 (4.8)       1 (5.0)       

BvFTD = behavioural variant of FTD; F = familial; F-AD = familial-autosomal dominant; LA = logopenic progressive aphasia; PNFA = progressive non-fluent aphasia; PPA U = primary progressive aphasia unspecified subtype; S = sporadic; SD = standard deviation ; U = unknown.

\*Percentage (%) within group of patients for whom we have information.

Of the seven *TBK1* carriers with FTD, one was also diagnosed with ALS (14.3%). ALS was so far not reported in any FTD patient with a *GRN* mutation. *C9orf72* carriers had the highest proportion of FTD-ALS patients with 23.1%. This was a significantly higher proportion than in familial non-mutation FTD patients (1.3%, *P* \< 0.001), sporadic non-mutation FTD patients (4.9%, *P* = 0.001) and non-mutation FTD patients with unknown familial history (3.7%, *P* = 0.001). Similar results were obtained when only including the index patients (*P* \< 0.001, *P* = 0.002 and *P* = 0.001, respectively). One of seven *TBK1* carriers was diagnosed with PPA, which was a similar proportion as in FTD patients caused by a *C9orf72* repeat expansion (14.3% versus 13.1%). The *GRN* carriers were the only patient group in which there was a higher proportion of PPA diagnoses in comparison to behavioural variant FTD diagnoses (47.6% PPA versus 45.2% behavioural variant FTD). *GRN* carriers presented significantly more often with PPA (mostly progressive non-fluent aphasia) compared to *C9orf72* carriers (13.1%, *P* \< 0.001) and sporadic non-mutation carriers (23.9%, *P* = 0.009). In the index patients-only analysis, there was only a significant difference in proportion of PPA patients between *GRN* carriers (7/16, 43.8%) and *C9orf72* carriers (7/47, 14.9%) (*P* = 0.033).

Behavioural disinhibition and social inappropriate behaviour was more frequent than apathy in *TBK1* carriers with behavioural variant FTD (83.3% and 16.7%, respectively). This is in contrast with *GRN* carriers who present significantly more often with apathy as the most prominent behavioural characteristic (87.5%, *P* = 0.004) ([Fig. 4](#awv358-F4){ref-type="fig"}B). In the behavioural variant FTD index patients-only analysis, 75.0% (3/4) of the *TBK1* carriers had behavioural disinhibition and social inappropriate behaviour as most prominent behavioural feature in comparison with only 16.7% (1/6) of the *GRN* carriers, although comparative analysis did not reveal significant differences (*P* = 0.190). *TBK1* carriers presented often with extrapyramidal symptoms (57.1%), which was significantly more often than *C9orf72* carriers (17.6%, *P* = 0.038) and borderline significantly more often than *GRN* carriers (18.9%, *P* = 0.054) ([Fig. 4](#awv358-F4){ref-type="fig"}C). In the index patients-only analysis, significance was reached for *TBK1* index carriers (3/5, 60.0%) in comparison with *GRN* carriers (1/14, 7.1%) (*P* = 0.037), but lost for *TBK1* carriers in comparison with *C9orf72* carriers (8/42, 19.0%) (*P* = 0.076). A high incidence of psychiatric symptoms such as psychosis, depression and substance abuse, was observed in *TBK1* carriers (57.1%). In all other patient groups, the proportion of patients with psychiatric symptoms was smaller, but in comparative analyses no significance was reached, although a borderline result was obtained in comparison with *GRN* carriers (18.9%) (*P* = 0.054) ([Fig. 4](#awv358-F4){ref-type="fig"}D). In the index patients-only analysis, a smaller proportion of *TBK1* carriers had psychiatric symptoms (2/5, 40.0%), which was not significantly more than in any other group.

Discussion
==========

Loss of function mutations in *TBK1* are the third most frequent cause of clinical FTD after *C9orf72* and *GRN* in the Belgian patient cohort, and the second most frequent cause of clinical ALS after *C9orf72* ([@awv358-B17]). Here, we described the detailed clinical characteristics of 16 *TBK1* carriers, of which six were clinically diagnosed with FTD, seven with ALS, one with FTD-ALS and two with unspecified dementia. Also, we provided the results of the genotype--phenotype characteristics of *TBK1* carriers compared to those of *C9orf72* and *GRN* carriers, and non-mutation carriers with FTD.

The age at onset of *TBK1* carriers was variable with a mean age at onset of 62 years. However, 75% of the *TBK1* carriers developed the disease after the age of 62, with two mutation carriers still unaffected at an age above 80. The latter carriers are members of Family DR158, in which the *TBK1* p.Glu643del mutation co-segregated with disease ([@awv358-B17]). This family has a high load of patients with psychiatric symptoms that may have complicated the diagnosis of FTD. Consequently, it is not excluded that early symptoms of FTD might have been wrongly interpreted in some carriers as psychiatric disease symptoms, or vice versa. However, our data suggest that the clinical penetrance of *TBK1* loss of function mutations might be incomplete as three carriers had no documented familial history of neurodegenerative disease and only 50% of the *TBK1* carriers from our cohort of index patients and relatives were affected by the age of 70.

The *TBK1* carriers with FTD developed the first symptoms significantly later than *C9orf72* carriers with FTD. However, this finding should be cautiously interpreted as the p.Glu643del mutation was over-represented among the *TBK1* carriers. Carriers of this specific mutation exhibited a milder phenotype with significantly later onset age (66.3 ± 3.9 years) and longer disease duration (8.3 ± 1.8 years) than carriers of another *TBK1* mutation ([@awv358-B17]). Two p.Glu643del carriers with ALS were siblings in Family DR663 and had remarkably young onset ages (Patient II.1, 51 years and Patient II.2, 41 years; [Fig. 1](#awv358-F1){ref-type="fig"}). These two ALS patients had also inherited a *C9orf72* expansion mutation as did a third sibling (Patient II.4) who only carried the *C9orf72* repeat expansion and was still unaffected at the age of 62 ([@awv358-B17]). This observation seems to support an interaction between the *TBK1* and *C9orf72* genes in patients carrying a mutation in both genes, lowering onset age ([@awv358-B6]). Another ALS carrier of p.Glu643del, Patient DR1044, ([Table 1](#awv358-T1){ref-type="table"}), carried a 'short' *C9orf72* expansion of 59 repeats units and had a disease onset at 63 years. We showed that *C9orf72* carriers of a short repeat expansion (range 45 to 80 repeat units), had a significantly later age at onset than those with long repeats ([@awv358-B18]).

The disease duration of *TBK1* carriers is relatively long, particularly in patients with FTD (8.2 ± 4.9 years). Though not significant, the disease duration was much shorter in *TBK1* carriers with ALS. These observations were in line with earlier observations in C*9orf72* carriers with ALS ([@awv358-B11]).

The majority of patients with FTD with a *TBK1* mutation were diagnosed with the behavioural variant of FTD. We found a comparable fraction of behavioural variant FTD in *TBK1* carriers as in *C9orf72* carriers, the latter known to present most often with behavioural variant FTD ([@awv358-B39]; [@awv358-B8]). Similar to these *C9orf72* carriers, behavioural disinhibition and social inappropriate behaviour was more frequent than apathy in *TBK1* carriers. This is in contrast with *GRN* carriers who more often presented with the language variant, mostly with progressive non-fluent aphasia ([@awv358-B9]; [@awv358-B10]; [@awv358-B15]), and in case of behavioural variant FTD, with apathy as the dominant feature ([@awv358-B2]).

Psychiatric symptoms were present in \>50% of the *TBK1* carriers. However, as six of the seven *TBK1* carriers with psychiatric symptoms belonged to the same Family DR158, we cannot draw firm conclusions regarding overall occurrence of psychiatric symptoms in *TBK1* carriers. As only five *TBK1* carriers with FTD were index patients, the non-significant result of the comparison with other mutation carriers only taking into account index patients is not sufficient to reject the hypothesis that *TBK1* carriers present more frequently with psychiatric symptoms. Therefore, research in larger cohorts of unrelated *TBK1* carriers will be needed.

Interestingly, memory loss and disorientation in time and/or space were common early in the disease course of *TBK1* carriers with FTD. Therefore, technical investigations were more often necessary to allow a clear differentiation between FTD and Alzheimer's disease. In Patient III.2 of Family DR158 ([Table 3](#awv358-T3){ref-type="table"}), doubt persisted in the clinical diagnosis between the frontal variant of Alzheimer's disease or FTD. This is in line with the observations by [@awv358-B31], who described a *TBK1* mutation in four patients with pathological diagnosis of FTLD or FTLD-MND of which two had a clinical diagnosis of Alzheimer's disease. Together, these observations suggest that screening of clinically diagnosed Alzheimer's disease patients for mutations in *TBK1* might be advisable*.* In Patient DR1124 ([Table 1](#awv358-T1){ref-type="table"}), who clinically presented with cognitive deficits and subsequently developed a rapidly evolving ALS phenotype, at autopsy we observed TDP-43 proteinopathy in the motor neurons while hyperphosphorylated tau pathology was present in the hippocampus ([Fig. 4](#awv358-F4){ref-type="fig"}) in the absence of other proteinopathies. The question remains whether this hippocampal tauopathy might explain the cognitive decline in the patient, or whether it is merely a sign of ageing associated tauopathy. Three *TBK1* carriers with ALS exhibited prominent upper motor neuron signs and in two of them no obvious electrophysiological evidence of lower motor neuron disease was present upon disease presentation. However, neuropathological examination in Patient DR1124 showed that TDP-43 and p62 positive neuronal cytoplasmic inclusions were mainly restricted to the lower motor neurons. Only one of the *TBK1* carriers was diagnosed with FTD-ALS, preventing a genotype--phenotype comparison with FTD-ALS patients carrying a *C9orf7*2 expansion mutation. ALS occurred in the current study in 23.1% of the *C9orf72* carriers in the Belgian FTD cohort, a similar result as the previous observation of 27% by [@awv358-B39]. In the same FTD cohort, none of the *GRN* carriers had ALS. *TBK1* carriers with FTD presented significantly more often with extrapyramidal symptoms than *C9orf72* carriers and, when only taking into account index patients, than *GRN* carriers. Noticeably, all *TBK1* carriers with extrapyramidal symptoms were carriers of the p.Glu643del mutation. Parkinsonism is said to occur in 20--30% of FTD patients ([@awv358-B30]), particularly linked to *MAPT* and *GRN* mutations ([@awv358-B22]; [@awv358-B1]; [@awv358-B4]). Future studies in larger cohorts of carriers of different *TBK1* mutations are needed to examine whether the association with extrapyramidal symptoms holds true.

Structural neuroimaging in *TBK1* carriers showed various patterns of cortical atrophy, which could be global or localized with frontotemporal predominance but also with involvement of the parietal regions, the hippocampus or the cerebellum. These variable findings are reminiscent of findings in *C9orf72* carriers who exhibited widespread patterns of atrophy with predominant atrophy of the frontal and, to a lesser extent, of the anterior temporal lobes, without regional specificity, and with involvement of the parietal lobes and the cerebellum ([@awv358-B43]). In contrast with the generally symmetric pattern of atrophy in *C9orf72* carriers ([@awv358-B3]; [@awv358-B26]), more than half of our *TBK1* carriers displayed an asymmetric pattern of atrophy (most frequently with right predominance). The variable widespread patterns are in contrast with the more characteristic patterns observed in *GRN* carriers who have most prominent atrophy in the temporal and parietal lobes ([@awv358-B41]; [@awv358-B34]) or in *MAPT* carriers who present with most prominent atrophy in the anteromedial temporal lobes ([@awv358-B42]; [@awv358-B34]). As in *C9orf72* carriers and *GRN* carriers, neuropathology of *TBK1* carriers is characterized by TDP-43 pathology. Neuropathological examination had been carried out in one FTD and one ALS patient and was compatible with TDP-43 type B proteinopathy, as was reported in other studies ([@awv358-B14]; [@awv358-B31]). One study also reported TDP-43 type A in *TBK1* carriers with FTD ([@awv358-B31]).

Our study has some limitations, as we identified in the Belgian patients a relatively low number of *TBK1* carriers and also lacked detailed clinical information on three of the carriers with ALS. Consequently, our observations in the genotype--phenotype comparisons with *C9orf72* carriers, *GRN* carriers and non-mutation carriers were often not or borderline significant and need to be examined in larger groups of *TBK1* carriers. Also, not all *TBK1* carriers received the same investigations, since this study was largely performed retrospectively. The fact that six *TBK1* carriers were members of the same family might have influenced some of our results, such as the high load of psychiatric symptoms, which might be due to other genetic factors shared among relatives.

In conclusion, carriers of a *TBK1* loss of function mutation have a variable, but on average late onset age (58.1 years in ALS patients and 63.3 years in FTD patients). Most patients with FTD present with behavioural variant FTD, with disinhibition as the most prominent feature. Memory loss is remarkably present in the initial phase of the disease. Extrapyramidal symptoms occur rather often, especially in carriers of the p.Glu643del mutation. On neuroimaging, various patterns of atrophy as well as of hypoperfusion or hypometabolism can be seen. Neuropathologically, *TBK1* carriers are characterized by TDP-43 pathology. Based on the observed genotype--phenotype correlations and the frequency of causal mutations in *C9orf72*, *GR*N and *TBK1* in our Belgian cohort, we propose the following guidelines for the genetic diagnostic setting. After a negative result for the *C9orf72* repeat expansion, which still remains the major cause for FTD-ALS and behavioural variant FTD, patients with FTD-ALS or behavioural variant FTD should preferably be tested first for loss of function mutations in *TBK1*, specifically in FTD patients with early memory difficulties in combination with behavioural problems. Furthermore, in patients with a relatively late onset age or in patients who present with extrapyramidal symptoms, *TBK1* loss of function mutations, especially the *TBK1* mutation p.Glu643del, should be considered.
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ALS

:   amyotrophic lateral sclerosis

FTD

:   frontotemporal dementia

FTLD

:   frontotemporal lobar degeneration

PPA

:   primary progressive aphasia

TDP-43

:   TAR DNA binding protein 43
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